Imperial College London
Portrait Picture

DrChiomaIzzi-Engbeaya

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

IPPRF Research Fellow
 
 
 
//

Contact

 

+44 (0)20 3313 3242c.izzi

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Abbara:2017:humrep/dex253,
author = {Abbara, A and Clarke, S and Islam, R and Prague, J and Comninos, A and Narayanaswamy, S and Papadopoulou, D and Roberts, R and Izzi-Engbeaya, C and Ratnasabapathy, R and Nesbitt, A and Vimalesvaran, S and Salim, R and Lavery, S and Bloom, S and Huson, L and Trew, G and Dhillo, W},
doi = {humrep/dex253},
journal = {Human Reproduction},
pages = {1915--1924},
title = {A second dose of kisspeptin safely optimizes oocyte maturation in women undergoing in IVF treatment: a phase 2 randomized controlled trial},
url = {http://dx.doi.org/10.1093/humrep/dex253},
volume = {32},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - STUDY QUESTIONCan increasing the duration of LH-exposure with a second dose of kisspeptin-54 improve oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS)?SUMMARY ANSWERA second dose of kisspeptin-54 at 10 h following the first improves oocyte yield in women at high risk of OHSS.WHAT IS KNOWN ALREADYKisspeptin acts at the hypothalamus to stimulate the release of an endogenous pool of GnRH from the hypothalamus. We have previously reported that a single dose of kisspeptin-54 results in an LH-surge of ~12–14 h duration, which safely triggers oocyte maturation in women at high risk of OHSS.STUDY DESIGN, SIZE, DURATIONPhase-2 randomized placebo-controlled trial of 62 women at high risk of OHSS recruited between August 2015 and May 2016. Following controlled ovarian stimulation, all patients (n = 62) received a subcutaneous injection of kisspeptin-54 (9.6 nmol/kg) 36 h prior to oocyte retrieval. Patients were randomized 1:1 to receive either a second dose of kisspeptin-54 (D; Double, n = 31), or saline (S; Single, n = 31) 10 h thereafter. Patients, embryologists, and IVF clinicians remained blinded to the dosing allocation.PARTICIPANTS/MATERIALS, SETTING, METHODSStudy participants: Sixty-two women aged 18–34 years at high risk of OHSS (antral follicle count ≥23 or anti-Mullerian hormone level ≥40 pmol/L).Setting: Single centre study carried out at Hammersmith Hospital IVF unit, London, UK.Primary outcome: Proportion of patients achieving an oocyte yield (percentage of mature oocytes retrieved from follicles ≥14 mm on morning of first kisspeptin-54 trigger administration) of at least 60%.Secondary outcomes: Reproductive hormone levels, implantation rate and OHSS occurrence.MAIN RESULTS AND THE ROLE OF CHANCEA second dose of kisspeptin-54 at 10 h following the first induced further LH-secretion at 4 h after administration. A higher proportion of patients achieved an oocyte yield ≥60% following a second dose of kisspepti
AU  - Abbara,A
AU  - Clarke,S
AU  - Islam,R
AU  - Prague,J
AU  - Comninos,A
AU  - Narayanaswamy,S
AU  - Papadopoulou,D
AU  - Roberts,R
AU  - Izzi-Engbeaya,C
AU  - Ratnasabapathy,R
AU  - Nesbitt,A
AU  - Vimalesvaran,S
AU  - Salim,R
AU  - Lavery,S
AU  - Bloom,S
AU  - Huson,L
AU  - Trew,G
AU  - Dhillo,W
DO  - humrep/dex253
EP  - 1924
PY  - 2017///
SN  - 1460-2350
SP  - 1915
TI  - A second dose of kisspeptin safely optimizes oocyte maturation in women undergoing in IVF treatment: a phase 2 randomized controlled trial
T2  - Human Reproduction
UR  - http://dx.doi.org/10.1093/humrep/dex253
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000416390500110&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/71154
VL  - 32
ER  -
Download